Prodigy System Advances Process for HLA in Stem Cell and Solid Organ
Transplant Research
Invitrogen, part of Life Technologies Corporation (NASDAQ:LIFE), today
announced the commercial availability of a state-of-the-art, automated,
research-use microarray system designed to simplify immunogenetic
testing, including human leukocyte antigen (HLA) research. The new
Prodigy™ system is an advanced DNA and protein analysis tool that
simplifies and accelerates histocompatibility research, vaccine and drug
development, and disease association studies.
The Prodigy system is the first high-throughput, next-generation,
sequence-specific oligonucleotide probe system that streamlines sample
workflow for hybridizing, detecting and analyzing HLA markers in
large-volume variation
analysis and genotyping research studies. HLA markers are
cell-surface proteins that play a key regulation role in the human
immune system, functioning as an alert mechanism when the body has been
invaded by foreign proteins or molecules, such as bacteria, parasites
and viruses. The Prodigy system represents a significant advancement in
technologies for this type of research, providing scientists with a
simplified workflow for cleaner, consistent and reproducible results,
while reducing hands-on interaction with the system, resulting in
decreased variability, errors and the need for repeat testing.
The Prodigy system features several technological advancements over
other systems in the market. It has 5-times the density capacity of
current bead-based assays and is enabled by push-button, walk-away
automation, enabling researchers to spend valuable time reviewing data
or preparing more samples. Prodigy is inherently scalable to include
multiplexing capability for more than 500 analytes, while providing high
resolution and unmatched efficiency and reliability.
It is also capable of industry-leading throughput that equates to
approximately 290 genotypes in 9 hours, and includes integrated software
that simplifies data analysis and interpretation. And, with capacity for
more than 500 analytes, the Prodigy system is uniquely scalable to
accommodate new alleles to be identified in the future, enabling it to
be easily incorporated into existing infrastructure.
